Are gonadotropin-releasing hormone agonists losing popularity? Current trends at a large fertility center

Fertility and Sterility

Volumn 93, Issue 1, 2010, Pages 101-108

  Reh, Andrea ^a   Krey, Lewis ^a   Noyes, Nicole ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

GnRH agonist; GnRH antagonist; in vitro fertilization; LH suppression; poor responder

Indexed keywords

GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LEUPRORELIN; LUTEINIZING HORMONE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DELIVERY; DRUG DOSE REDUCTION; DRUG USE; EMBRYO; FEMALE; FERTILITY; FERTILIZATION IN VITRO; GROUPS BY AGE; HEALTH CENTER; HUMAN; LOW DRUG DOSE; LUTEAL PHASE; OUTCOME ASSESSMENT; POPULATION; PREGNANCY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNIVERSITY;

ADULT; AGE FACTORS; EMBRYO IMPLANTATION; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; INFERTILITY; LIVE BIRTH; LUTEINIZING HORMONE; MALE; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PREGNANCY; PREGNANCY RATE; REPRODUCTIVE TECHNIQUES, ASSISTED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 72749092881     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.09.048     Document Type: Article

References (34)

1. Hughes E.G., Fedorkow D.M., Daya S., Sagle M.A., Van de Koppel P., and Collins J.A. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 58 (1992) 888-896
2. Tan S.L., Maconochie N., Doyle P., Campbell S., Balen A., Bekir J., et al. Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin. Am J Obstet Gynecol 171 (1994) 513-520
3. Hugues J.N. Cedrin Durnerin IC. Revisiting gonadotrophin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins. Hum Reprod Update 4 (1998) 83-101
4. Kowalik A., Barmat L., Damario M., Liu H.C., Davis O., and Rosenwaks Z. Ovarian estradiol production in vivo. Inhibitory effect of leuprolide acetate. J Reprod Med 43 (1998) 413-417
5. Feldberg D., Farhi J., Ashkenazi J., Dicker D., Shalev J., and Ben-Rafael Z. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. Fertil Steril 62 (1994) 343-346
6. Olivennes F., Righini C., Fanchin R., Torrisi C., Hazout A., Glissant M., et al. A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patients with high follicle-stimulating hormone concentrations on day 3. Hum Reprod 11 (1996) 1169-1172
7. Olivennes F., Belaisch-Allart J., Emperaire J.C., Dechaud H., Alvarez S., Moreau L., et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 73 (2000) 314-320
8. Copperman A.B. Antagonists in poor-responder patients. Fertil Steril 80 Suppl 1 (2003) S16-S24 discussion S32-4
9. Scott R.T., and Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril 61 (1994) 880-885
10. Schoolcraft W., Schlenker T., Gee M., Stevens J., and Wagley L. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol. Fertil Steril 67 (1997) 93-97
11. Surrey E.S., Bower J., Hill D.M., Ramsey J., and Surrey M.W. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertil Steril 69 (1998) 419-424
12. Akman M.A., Erden H.F., Tosun S.B., Bayazit N., Aksoy E., and Bahceci M. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod 16 (2001) 868-870
13. Malmusi S., La Marca A., Giulini S., Xella S., Tagliasacchi D., Marsella T., et al. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation. Fertil Steril 84 (2005) 402-406
14. Leung P.C., Cheng C.K., and Zhu X.M. Multi-factorial role of GnRH-I and GnRH-II in the human ovary. Mol Cell Endocrinol 202 (2003) 145-153
15. Kenigsberg D., Littman B.A., and Hodgen G.D. Medical hypophysectomy. I Dose-response using a gonadotropin-releasing hormone antagonist. Fertil Steril 42 (1984) 112-115
16. Frydman R., Cornel C., de Ziegler D., Taieb J., Spitz I.M., and Bouchard P. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation. Fertil Steril 56 (1991) 923-927
17. Diedrich K., Diedrich C., Santos E., Zoll C., al-Hasani S., Reissmann T., et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 9 (1994) 788-791
18. Olivennes F., Fanchin R., Bouchard P., de Ziegler D., Taieb J., Selva J., et al. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program. Fertil Steril 62 (1994) 468-476
19. Borm G., and Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 15 (2000) 1490-1498
20. Mahutte N.G., and Arici A. Role of gonadotropin-releasing hormone antagonists in poor responders. Fertil Steril 87 (2007) 241-249
21. Akman M.A., Erden H.F., Tosun S.B., Bayazit N., Aksoy E., and Bahceci M. Addition of GnRH antagonist in cycles of poor responders undergoing IVF. Hum Reprod 15 (2000) 2145-2147
22. Craft I., Gorgy A., Hill J., Menon D., and Podsiadly B. Will GnRH antagonists provide new hope for patients considered "difficult responders" to GnRH agonist protocols?. Hum Reprod 14 (1999) 2959-2962
23. Fasouliotis S.J., Laufer N., Sabbagh-Ehrlich S., Lewin A., Hurwitz A., and Simon A. Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF. J Assist Reprod Gen 20 (2003) 455-460
24. Marci R., Caserta D., Dolo V., Tatone C., Pavan A., and Moscarini M. GnRH antagonist in IVF poor-responder patients: results of a randomized trial. Reprod Biomed Online 11 (2005) 189-193
25. European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 16 (2001) 644-651
26. Al-Inany H.G., Abou-Setta A.M., and Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 3 (2006) CD001750
27. Shanbhag S., Aucott L., Bhattacharya S., Hamilton M.A., and McTavish A.R. Interventions for "poor responders" to controlled ovarian hyperstimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev 4 (2007) CD004379
28. Practice Committee of the Society for Assisted Reproductive Technology; Practice Committee of the American Society for Reproductive Medicine. Guidelines on number of embryos transferred. Fertil Steril 86 5 Suppl (2006) S51-S52
29. Griesinger G., Diedrich K., Tarlatzis B.C., and Kolibianakis E.M. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 13 (2006) 628-638
30. Cardone V.S. GnRH antagonists for treatment of polycystic ovarian syndrome. Fertil Steril 80 Suppl 1 (2003) S25-S31 discussion S2-4
31. Ragni G., Vegetti W., Riccaboni A., Engl B., Brigante C., and Crosignani P.G. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 20 (2005) 2421-2425
32. Bahceci M., Ulug U., Ben-Shlomo I., Erden H.F., and Akman M.A. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. J Reprod Med 50 (2005) 84-90
33. Hwang J.L., Seow K.M., Lin Y.H., Huang L.W., Hsieh B.C., Tsai Y.L., et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. Hum Reprod 19 (2004) 1993-2000
34. Sunkara S.K., Tuthill J., Khairy M., El-Toukhy T., Coomarasamy A., Khalaf Y., et al. Pituitary suppression regimens in poor responders undergoing IVF treatment: a systematic review and meta-analysis. Reprod Biomed Online 15 (2007) 539-546